Oxnard G.RThress K.SAlden R.SLawrance RPaweletz C.PCantarini MBarrett CCHIH-HSIN YANGJänne P.2020-05-262020-05-2620161556-0864https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015248073&doi=10.1016%2fS1556-0864%2816%2930328-8&partnerID=40&md5=08576bb7b4e8cebb25cfeb3aeaf4f83ahttps://scholars.lib.ntu.edu.tw/handle/123456789/494980[SDGs]SDG2[SDGs]SDG3epidermal growth factor receptor; osimertinib; advanced cancer; Article; cohort analysis; controlled study; drug response; EGFR gene; false negative result; gene mutation; genotype; human; major clinical study; non small cell lung cancer; priority journal; progression free survival; treatment outcome135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLCjournal article10.1016/S1556-0864(16)30328-82-s2.0-85015248073